Onxeo Meets US Investors During “French Life Sciences Days” Event in New York on June 17 & 18, 2015

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, announced today its participation in the “French Life Sciences Days” to
be held in New York on June 17 & 18, 2015.

Initiated by France Biotech, the event “French Life Sciences Days” aims to bring
together French Life Sciences companies listed on stock market with the North
American financial community. Given the great success of its first edition of
June 2014, France Biotech renews this event to enable innovative SMEs to promote
their achievements and attractiveness towards specialized US-based investors.

During this event, about 20 French Biotech Medtech and Cleantech, including
Onxeo will present and hold face-to-face meetings with specialized North
American investment funds, banks, financial analysts. This event will also be
widely covered by the medias in France and in the US.

« US investors show a growing level interest in the French Biotech companies’
innovations and breakthroughs. The “Life Sciences Days” event in New York is an
excellent opportunity for Onxeo to reinforce its visibility with these
specialized US investors, to strengthen their knowledge about recent company’s
achievements and future growth strategy ”, comments Judith Greciet, CEO of Onxeo
and board member of France Biotech association.

“French Life Sciences Days”, June 18, 2015 - W Hotel, 541 Lexington Avenue, New
York, NY 10022, United States

About « French Life Sciences Days »
This new initiative of France Biotech aims to strenghten links between French
listed companies and investors from different countries, and thus to promote
exchange of information while demonstrating the strength of our financial
market. It aims to bring together the key players in Paris (banks, brokers,
analysts, auditors, lawyers, communication agencies) combined in a sponsorship
committee what will accompany the entrepreneurs. On this occasion, the French
companies of Life Sciences listed on NYSE Euronext will present their
innovations and breakthroughts to international investors.

About France Biotech Biotech
France Biotech brings together French life science companies and their expert
partners. Its mission is to support the development of the French life sciences
by working for a favorable legislative and fiscal environment. France Biotech
catalyzed the French government's creation of a special fiscal status for start
ups in 2004 and continues to act as an advocate for this innovative sector. The
organization is currently chaired by Pierre-Olivier Goineau, Co-Founder of
ERYTECH Pharma. France Biotech has over 150 members and is governed by a Board
of 20 life science entrepreneurs.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

To receive our press releases and newsletters, please register on:
http://www.onxeo.com/en/newsletter/
Follow us on twitter @Onxeo_
Contacts
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol, +33 6 64 18 99 59
onxeo@alizerp.com